Related Experiment Video
Updated: Jan 7, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Subsequent risk of death from sepsis among over 6 million cancer patients: A population-based cohort study
Hang Yi1, Xu Ou-Yang2, Mingzhong Wan2
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Background:
Sepsis, a severe systemic inflammatory response to infection, remains a leading cause of morbidity and mortality among cancer patients, particularly due to the immunosuppressive effects of both malignancy and its treatments. This study aims to assess the risk of sepsis-related mortality in cancer patients, identify the effects of various cancer types and demographic factors, and provide insights for developing targeted preventive strategies.
Methods:
A population-based cohort study was conducted using data from the Surveillance, Epidemiology, and End Results (SEER) database, which includes approximately 26.5 % of the U.S.
Population:
The analysis covered 6,891,191 cancer patients diagnosed from 2000 to 2021. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated to compare sepsis-related mortality risk in cancer patients with the general population. Key variables included cancer type, age, gender, race, and marital status.
Results:
Of the 6,891,191 cancer patients included, 25,232 (0.37 %) died from sepsis. The overall SMR was 1.52 (95 % CI: 1.50-1.54), with an AER of 2.15 (95 % CI: 2.05-2.25) per 10,000 person-years. Patients with brain and other nervous system cancers (SMR = 5.74, 95 % CI: 4.95-6.61), respiratory system cancers (SMR = 3.52, 95 % CI: 3.38-3.66), and hematologic malignancies such as myeloma (SMR = 3.25, 95 % CI: 2.97-3.55) exhibited high sepsis-related mortality risks. Disparities were observed, with elevated risks in female patients (SMR = 1.64, 95 % CI: 1.61-1.67), American Indian/Alaska Native patients (SMR = 4.23, 95 % CI: 3.50-5.07), and single (never married) individuals (SMR = 2.50, 95 % CI: 2.42-2.58). Mortality risk was most pronounced within the first two months following cancer diagnosis, with an SMR of 7.37 (95 % CI: 7.14-7.61).
Conclusions:
The findings suggest a significantly increased risk of sepsis-related mortality among cancer patients, highlighting the need for improved infection prevention, early interventions, and tailored strategies. Multidisciplinary care and enhanced support for high-risk groups are essential to mitigate sepsis-related complications and improve outcomes.
Related Concept Videos
Cancer Survival Analysis
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Relative Risk
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

